Pulmonary embolism associated with olanzapine

Ian del Conde; Samuel Z. Goldhaber

doi:10.1160/TH06-08-0419

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 96(05): 690-691
DOI: 10.1160/TH06-08-0419

Case Report

Schattauer GmbH

Pulmonary embolism associated with olanzapine

Ian del Conde

¹Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

,

Samuel Z. Goldhaber

¹Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

²Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

› Author Affiliations

Abstract

Full Text

References

References
1 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (Suppl. 01) I4-18.
2 Piazza G, Goldhaber SZ. Acute pulmonary embolism: part I: epidemiology and diagnosis. Circulation 2006; 114: e28-e32.
3 Schoepf UJ, Kucher N, Kipfmueller F. et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004; 110: 3276-80.
4 Scridon T, Scridon C, Skali H. et al. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol 2005; 96: 303-5.
5 Toki S, Morinobu S, Yoshino A. et al. A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics. J Clin Psychiatry 2004; 65: 1576-7.
6 Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219-23.
7 Walker AM, Lanza LL, Arellano F. et al. Mortality in current and former users of clozapine. Epidemiology 1997; 08: 671-7.
8 Hagg S, Tatting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol 2003; 18: 299-300.
9 Liperoti R, Pedone C, Lapane KL. et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165: 2677-82.
10 Boullin DJ, Woods HF, Grimes RP. et al. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol 1975; 02: 29-35.
11 Wallaschofski H, Eigenthaler M, Kiefer M. et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 2003; 23: 479-83.
12 Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies. A prevalence study. Biol Psychiatry 1990; 27: 863-70.
13 Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155-6.
14 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
15 Brandao LR, Williams S, Kahr WH. et al. Exerciseinduced deep vein thrombosis of the upper extremity. 1. Literature review. Acta Haematol 2006; 115: 214-20.
16 Arnone D, Hansen L, Davies G. Pulmonary embolism and severe depression. Am J Psychiatry 2002; 159: 873-4.
17 Hamanaka S, Kamijo Y, Nagai T. et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J 2004; 68: 850-2.